Thomas Shum, MD, PhD

Thomas Shum, MD, PhD

Emergency / Teleradiology

Nuclear Medicine / PET Imaging

Undergraduate

Bachelor of Science,
Pharmaceutical Sciences
Purdue University
West Lafayette, IN

Medical School

Baylor College of Medicine
Medical Scientist Training Program
Houston, TX

Internship

University of Maryland Medical Center
Midtown Campus
Baltimore, MD

Residency

Diagnostic Radiology
The Brigham and Women’s Hospital
Harvard Medical School
Boston, MA

Biography

Dr. Thomas Shum is a highly qualified radiologist specializing in Nuclear Medicine/PET Imaging and a valued member of the Emergency/Radiology team at Consulting Radiologists, Ltd. He completed his Bachelor of Science in Pharmaceutical Sciences at Purdue University in West Lafayette, IN, before pursuing his M.D. and Ph.D. through the Medical Scientist Training Program at Baylor College of Medicine in Houston, TX. Dr. Shum’s postgraduate training includes an internship at the University of Maryland Medical Center’s Midtown Campus in Baltimore, MD, followed by a residency in Diagnostic Radiology at The Brigham and Women’s Hospital, Harvard Medical School in Boston, MA. During his diagnostic radiology residency, he also completed a 16-month eligibility pathway for dual certification in nuclear medicine through the Joint Program in Nuclear Medicine (JPNM) at the Brigham and Women’s Hospital.

As a diagnostic radiologist and nuclear medicine physician, Dr. Shum finds great satisfaction in providing vital diagnostic information that guides patient care and treatment strategies. He particularly enjoys utilizing FDG PET/CT studies for cancer staging and restaging, which allows for precise assessment of treatment effectiveness in cancer patients.

Outside of his professional pursuits, Dr. Shum maintains a balanced lifestyle. He enjoys reading, cooking, working out, and exploring new cities and countries. These activities not only provide personal fulfillment but also contribute to his well-rounded approach to life and medicine.

Dr. Shum’s commitment to advancing medical science is evident in his notable achievement as the primary inventor of C7R, a novel protein developed during his Ph.D. studies at Baylor College of Medicine. This groundbreaking innovation enhances chimeric antigen receptor (CAR) T-cell immunotherapy for cancer treatment. As of August 2024, two clinical trials utilizing C7R in CAR T-cell therapy have shown promising results in cancer patients, marking a significant contribution to the field of oncology and demonstrating Dr. Shum’s dedication to improving patient outcomes through innovative research.

PRACTICE PHILOSOPHY

It is a privilege to serve patients and to put patient care first.

Organizations

  • American Society for Gene and Cell Therapy
  • Radiological Society of North America